NASDAQ:VIVS VivoSim Labs (VIVS) Stock Price, News & Analysis $0.21 +0.01 (+4.20%) As of 01:02 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About VivoSim Labs Stock (NASDAQ:VIVS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VivoSim Labs alerts:Sign Up Key Stats Today's Range$0.20▼$0.2150-Day Range$0.20▼$0.4752-Week Range$0.20▼$3.54Volume302,811 shsAverage Volume2.55 million shsMarket Capitalization$3.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. Read More VivoSim Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreVIVS MarketRank™: VivoSim Labs scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingVivoSim Labs has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVivoSim Labs has only been the subject of 1 research reports in the past 90 days.Read more about VivoSim Labs' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of VivoSim Labs is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VivoSim Labs is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.44% of the float of VivoSim Labs has been sold short.Short Interest Ratio / Days to CoverVivoSim Labs has a short interest ratio ("days to cover") of 1.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VivoSim Labs has recently decreased by 20.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVivoSim Labs does not currently pay a dividend.Dividend GrowthVivoSim Labs does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.15 News SentimentVivoSim Labs has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for VivoSim Labs this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for VIVS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added VivoSim Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, VivoSim Labs insiders have not sold or bought any company stock.Percentage Held by Insiders1.00% of the stock of VivoSim Labs is held by insiders.Percentage Held by Institutions8.23% of the stock of VivoSim Labs is held by institutions.Read more about VivoSim Labs' insider trading history. Receive VIVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VivoSim Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIVS Stock News HeadlinesCritical Survey: Bio-Techne (NASDAQ:TECH) versus VivoSim Labs (NASDAQ:VIVS)September 27 at 5:28 AM | americanbankingnews.comAnalyzing Quantum-Si (NASDAQ:QSI) & VivoSim Labs (NASDAQ:VIVS)September 24, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 30 at 1:00 AM | Behind the Markets (Ad)VivoSim Labs Inc. (NASDAQ: VIVS) Uses Human 3D Biology to Streamline Drug DevelopmentSeptember 23, 2026 | marketscreener.comMCritical Review: VivoSim Labs (NASDAQ:VIVS) and Caris Life Sciences (NASDAQ:CAI)September 22, 2026 | americanbankingnews.comVivoSim Labs Presents New NAMkind Data At EUROTOX 2026September 16, 2026 | rttnews.comVivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCsSeptember 16, 2026 | financialpost.comFVivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCsSeptember 16, 2026 | globenewswire.comSee More Headlines VIVS Stock Analysis - Frequently Asked Questions How have VIVS shares performed this year? VivoSim Labs' stock was trading at $1.81 at the beginning of the year. Since then, VIVS shares have decreased by 88.3% and is now trading at $0.2110. How were VivoSim Labs' earnings last quarter? VivoSim Labs, Inc. (NASDAQ:VIVS) released its earnings results on Wednesday, August, 12th. The company reported ($0.25) EPS for the quarter. The business earned $0.02 million during the quarter. VivoSim Labs had a negative net margin of 11,016.07% and a negative trailing twelve-month return on equity of 612.23%. How do I buy shares of VivoSim Labs? Shares of VIVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/12/2026Today9/30/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VIVS's financial health is in the Red zone, according to TradeSmith. VIVS has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:VIVS CIK1497253 Weborganovo.com Phone(858) 224-1000FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.84 million Net Margins-11,016.07% Pretax Margin-11,011.61% Return on Equity-612.23% Return on Assets-177.02% Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio1.70 Sales & Book Value Annual Sales$130 thousand Price / Sales26.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.42) per share Price / Book-0.50Miscellaneous Outstanding Shares16,590,000Free Float16,420,000Market Cap$3.47 million OptionableN/A Beta1.45 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:VIVS) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersLegendary U.S. Congressman Issues WarningDr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThere’s no stopping this train…Biotech IPOs have already doubled last year's total in 2026, and key biotech indices returned over 56 percent ...Porter & Company | SponsoredPeople paid $8,000… yours for FREESome investors paid $8,000 to sit in the room with Luke Lango in Las Vegas. He says the new Elon venture he...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VivoSim Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VivoSim Labs With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIVS Stock Alerts